France's Pharnext Attracts Business Leaders As Investors; Uses Network Pharmacology For New Low-Dose Combos
This article was originally published in The Pink Sheet Daily
Executive Summary
French industrialists invest in a Series B fundraising for Pharnext, attracted by its network pharmacology approach to neurological and other diseases.